Hexarelin
Hexarelin is a synthetic hexapeptide GHRP and among the most potent ghrelin receptor agonists in its class, producing GH pulses substantially larger than GHRP-2 or GHRP-6 at equivalent doses in pharmacodynamic studies. Beyond its GH secretagogue activity, hexarelin has been shown to directly activate CD36 scavenger receptors in cardiac tissue, producing cardioprotective effects in animal models of heart failure and ischemia that are independent of GH elevation — a mechanistically distinct property not shared by other GHRPs. Its potency also means pronounced tachyphylaxis: GH response attenuates quickly with continuous dosing, making cycling protocols important to maintain efficacy. Prolactin and cortisol co-stimulation are notable, and human data remain limited to pharmacokinetic and early exploratory studies with no regulatory approval.
Evidence last reviewed: 19 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence base for hexarelin includes low-quality studies showing hormonal changes and potential cardioprotective effects. However, the gaps in human data and lack of regulatory approval highlight the need for caution in its use.
GH secretionPatients with alcohol pseudo-Cushing's syndrome and Cushing's disease · RCTLow
Hexarelin induced significant ACTH/cortisol responses in patients with Cushing's disease.
Hormonal changesSubjects with alcohol pseudo-Cushing's syndrome, Cushing's disease, and normal controls · RCTLow
Hexarelin induced hormonal changes, including ACTH/cortisol responses, in different subject groups.
CardioprotectionGeneral population · Case seriesVery low
Hexarelin may provide cardioprotective effects through direct activation of cardiac receptors.